Kineta Inc.

Drug Discovery

Kineta is the parent company of Kineta Immuno-Oncology.   The parent company discovers and develops antiviral therapies and immune-modulating drugs for the treatment of RNA viruses that include hepatitis C, influenza, West Nile virus, and the common cold. It offers ShK Analogs for treatment of multiple sclerosis and autoimmune diseases; and RIG-I Pathway, a molecular on/off switch that triggers the human body’s immune defenses against virus infection.

Cantilever holds common shares in this company.